BRISTOL-MYERS SQUIBB COMPANY Remaining Share Repurchase Authorization
BRISTOL-MYERS SQUIBB COMPANY (BMY) had Remaining Share Repurchase Authorization of $5.00 billion as of 2025-12-31, per its 10-K filed 2026-02-11.
Financial Statements › Notes › Equity
us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1 · last filed 2026-02-11
- 2025-12-31: Stock Repurchase Program, Remaining Authorized Repurchase Amount $5.00B.
- 2024-12-31: Stock Repurchase Program, Remaining Authorized Repurchase Amount $5.00B.
- 2023-12-31: Stock Repurchase Program, Remaining Authorized Repurchase Amount $5.00B.
- 2023-09-30: Stock Repurchase Program, Remaining Authorized Repurchase Amount $2.00B.
| Period end | Stock Repurchase Program, Remaining Authorized Repurchase Amount |
|---|---|
| 2025-12-31 | $5.00B 10-K · filed 2026-02-11 |
| 2024-12-31 | $5.00B 10-K · filed 2025-02-12 |
| 2023-12-31 | $5.00B 10-K · filed 2024-02-13 |
| 2023-09-30 | $2.00B 10-Q · filed 2023-10-26 |
| 2023-06-30 | $6.00B 10-Q · filed 2023-07-27 |
| 2023-03-31 | $6.90B 10-Q · filed 2023-04-27 |
| 2022-12-31 | $7.20B 10-K · filed 2023-02-14 |
| 2022-09-30 | $9.50B 10-Q · filed 2022-10-26 |
| 2022-06-30 | $10.20B 10-Q · filed 2022-07-27 |
| 2022-03-31 | $10.20B 10-Q · filed 2022-04-29 |
| 2021-12-31 | $15.20B 10-K · filed 2023-02-14 |
| 2021-09-30 | $2.90B 10-Q · filed 2021-10-27 |
| 2021-06-30 | $3.40B 10-Q · filed 2021-07-28 |
| 2021-03-31 | $4.60B 10-Q · filed 2021-04-29 |
| 2020-12-31 | $4.40B 10-K · filed 2022-02-09 |
| 2020-09-30 | $5.90B 10-Q · filed 2020-11-05 |
| 2020-06-30 | $5.90B 10-Q · filed 2020-08-06 |
| 2020-03-31 | $5.90B 10-Q · filed 2020-05-07 |
| 2020-01-01 | $1.00B 10-Q · filed 2020-05-07 |
| 2019-12-31 | $1.00B 10-Q · filed 2020-11-05 |
| 2019-09-30 | $1.00B 10-Q · filed 2019-10-31 |
| 2016-09-30 | $1.10B 10-Q · filed 2016-10-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |